ClinicalTrials.gg
RecruitingNCT06847074Updated Jun 11, 2026

Rise & Shine: Promoting Sleep Quality in Chronic Stroke With Exercise

An interventional study of Multimodal Exercise and Cognitve and Social Activities in Stroke and Poor Quality Sleep, sponsored by University of British Columbia. Recruiting at 1 site in Canada. Open to participants aged 55 Years and older. Per ClinicalTrials.gov, last updated 2026-06-11.

Sponsored by University of British Columbia · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started May 2025; still recruiting 1 year 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
62
Allocation
Randomized
Ages
55 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 30 studies in Stroke by University of British Columbia — 3 open to participants now, 4 under way, none of them phase 3. Stroke · University of British Columbia.

Planned enrollment
13th of 25
62 · median 62
Started
2025
the only one that year
No phase
24 of 30
3 open now
Registered
29th of 30
by date

Among the 30 studies in Stroke by University of British Columbia, this one is the 13th largest by planned enrollment of the 25 interventional ones that give a count, is the only one that started in 2025, is one of 24 with no phase, and was the 29th registered.

Stroke

8,283 studies on the registry are indexed under Stroke; 2,065 are open to participants now.

Browse Stroke studies →

Open to participants now

3 of the 30 studies in Stroke by University of British Columbia are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Who these studies take

Of the 1,418 Stroke studies recruiting now, 698 (49%) set no upper age limit and 281 (20%) stop at 75 or younger; 77 take children under 18; 197 take healthy volunteers.

This study: 55 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 30 studies in Stroke by University of British Columbia, or all of them as a file.
02

Study summary

health problems, such as heart disease, diabetes, cognitive impairment, and dementia.

After a person suffers a stroke, they often experience difficulties in getting a good night's sleep. Approximately half of stroke survivors have insomnia, or have trouble falling and/or staying asleep. Poor sleep quality among stroke survivors increases the risk of recurrent stroke by 3-fold and the risk of early death by 76%. Hence, stroke survivors need strategies to promote better sleep.

Fortunately, evidence shows that sleep quality can be improved with exercise, even among those who struggle with insomnia. Whether exercise training can improve sleep quality in adults with chronic stroke (i.e., at least 12 months has passed since their stroke) and poor sleep quality is not known. In addition, it is unknown if improved sleep is associated with improved outcomes in those with chronic stroke.

This study will specifically evaluate the effect of twice-weekly targeted exercise training on sleep quality over a 6-month period in persons with chronic stroke and poor sleep quality. This study will also evaluate the effect of exercise on the following outcomes: 1) sleep structure; 2) fatigue; 3) daytime sleepiness; 4) mood; 5) physical function and capacity; 6) thinking abilities; 7) heart health; and 8) quality of life. Finally, this study will examine how changes in sleep quality may be related to changes in these outcomes. Our proposed research is timely as the importance of sleep to recovery, health, and wellbeing post-stroke is increasingly recognized.

Read the detailed description

Approximately half of stroke survivors have insomnia. Poor sleep quality among stroke survivors increases the risk of recurrent stroke by 3-fold and the risk of early death by 76%. Hence, stroke survivors are a target population in need of intervention strategies to promote sleep quality.

Current research and stroke rehabilitation do not address the sleep consequences of stroke - especially for those in the chronic phase (i.e., = or > 12 months since an index stroke). Adults with chronic stroke have lower sleep efficiency compared with sex- and age-matched controls. Poor sleep quality in chronic stroke is associated with depression, impaired physical function, and reduced cognitive function.

How to effectively treat insomnia in adults with chronic stroke is not well established. Intervention studies show exercise improves sleep quality and structure. Whether exercise can improve sleep quality in adults with chronic stroke and poor sleep quality is not established.

Primary Question: In adults with chronic stroke and poor sleep quality, can a 26-week multimodal exercise training program of moderate intensity (EX) improve sleep efficiency, as objectively measured by the actigraphy, compared with a 26-week cognitive and social activities program (CON; active control group)?

Secondary Question: What are additional benefits of EX vs. CON? Compared with CON, we will evaluate the effect of EX on: 1) actigraphy-measured sleep parameters of latency, duration, and wake after sleep onset; 2) sleep architecture by frontal electroencephalography; 3) subjective sleep quality; 4) fatigue; 5) daytime sleepiness; 6) mood; 7) functional capacity; 8) cognitive function; 9) cardiometabolic risk factors; and 10) quality of life.

Tertiary Question: Are changes in sleep quality associated with changes in: 1) fatigue; 2) daytime sleepiness; 3) mood; 4) cognitive function; 5) cardiometabolic risk factors; and 6) quality of life?

Pilot Data: Using actigraphy, the investigators acquired sleep data from 21 of 120 (i.e., subset) participants with chronic stroke enrolled in a RCT with cognitive function as the primary outcome. These 21 participants (mean age=69) were randomized to 26 weeks of: 1) multimodal exercise of moderate intensity (EX; n=12); or 2) cognitive and social activities (i.e., no exercise; CON; n=9). Of these 21 participants, 48% had a baseline actigraphy-measured sleep efficiency \< 85%. Compared with CON, EX significantly improved actigraphy-measured sleep efficiency values (in %) at 13 weeks and 26 weeks.

Methods: A 26-week, assessor-blinded, single-site RCT of 62 community-dwelling adults with chronic stroke, WatchPAT measured sleep efficiency \< 85%, Pittsburgh Sleep Quality Index global score > 5, and aged 55 years and older. Individuals will be randomized to one of two experimental groups: 1) twice-weekly EX (n=31); or 2) twice-weekly CON (n=31). Randomization will be stratified by sex and age. Measurement will occur at baseline, 13 weeks, and 26 weeks, unless otherwise stated.

03

Conditions studied

  • Stroke
  • Poor Quality Sleep

Keywords

  • Exercise
04

Who can participate

Ages eligible
55 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

We will include community-dwelling adults who had an ischemic or hemorrhagic stroke at least one year prior to study enrolment and have poor sleep quality - defined as a sleep efficiency of \< or = 85%, with allowance for minor upward deviations on individual nights consistent with known night-to-night variability and instrument accuracy limits, and a PSQI global score of > 5. Individuals must also meet these inclusion criteria: 1) aged 55 years and older; 2) a baseline score of = or > 22/30 and a MoCA score of = or > 19/30; 3) community-dwelling; 4) able to comply with scheduled assessments, classes, and other trial procedures; 5) read, write, and speak English with acceptable visual and auditory acuity; 6) not to start or stable (i.e., = or > 6 months) on a fixed dose of medication that impacts sleep (i.e., anti-arrhythmics, beta blockers, selective serotonin reuptake inhibitor, etc.) during the 26-week intervention period; 7) able to walk for a minimum of six metres with rest intervals with or without assistive devices; 8) based on interview, have an activity tolerance of 60 minutes with rest intervals; 9) not participating in any regular therapy or progressive exercise (e.g., treadmill or weight-lifting); and 10) able to safely engage in exercise as indicated by the PAR-Q+63 and written confirmation by family or study physicians.

Exclusion criteria

Exclusion Criteria:

We will exclude individuals who: 1) are diagnosed with OSA and are not using CPAP or defined as potentially having undiagnosed OSA (AHI > 20) as a result of study screening; 2) have restless leg syndrome; 3) are diagnosed with dementia of any type; 4) are diagnosed with another type of neurodegenerative or neurological condition (e.g., Parkinson's disease); 5) are planning to participate, or already enrolled in, a clinical drug trial or exercise trial concurrent to this study; 6) are at high risk for cardiac complications during exercise and/or unable to self-regulate activity or to understand recommended activity level; 7) have peripheral neuropathy or severe musculoskeletal or joint disease that impairs mobility, as determined by his/her physician; or 8) have aphasia as judged by an inability to communicate by phone.

Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Care provider, Investigator, Outcomes assessor)
Enrollment
62 participants (estimated)

Study arms

  • Experimental
    Multimodal Exercise Training

    The program will consist of moderate intensity, multimodal exercise training; 2x/week; in-person, group-based.

    Behavioral: Multimodal Exercise

  • Active comparator
    Cognitive and Social Activities (No Exercise)

    The program will consist of cognitive and social activites; 2x/week; in-person, group-based

    Behavioral: Cognitve and Social Activities

Interventions

  • BehavioralMultimodal Exercise

    Each 60-minute class will include a 10-minute warm-up (i.e., stretches for the major muscles and walking on the spot), 40 minutes of training, and a 10-minute cool down (i.e., stretches and relaxation techniques).Instructors will use heart rate monitors to continuously track intensity during and across all sessions.

  • BehavioralCognitve and Social Activities

    Each 60-minute class will include 30 minutes of cognitive enrichment activities and 30 minutes of activities that promote social interactions.

06

What researchers measure

Primary outcomes

  1. Sleep Efficiency

    Sleep efficiency as measured by actigraphy over days of wear.

    Time frame: Baseline, 13 weeks, 26 weeks

Secondary outcomes

  1. Sleep latency, duration, and wake after sleep onset

    Sleep latency, duration, and wake after sleep onset by actigraphy over days of wear.

    Time frame: Baseline, 13 weeks, 26 weeks

  2. Sleep Architecture (OPTIONAL)

    Sleep architecture as measured by EEG headband

    Time frame: Baseline, 13 weeks, 26 weeks

  3. Subjective sleep quality

    Subjective sleep quality measured by Pittsburgh Sleep Quality Index

    Time frame: Baseline, 13 weeks, 26 weeks

  4. Fatigue

    Fatigue measured by Fatigue Severity Scale

    Time frame: Baseline, 13 weeks, 26 weeks

  5. Sleepiness

    Daytime sleepiness measured by questionnaire

    Time frame: Baseline, 13 weeks, 26 weeks

  6. Mood

    Depressive symptoms measured by questionnaire

    Time frame: Baseline, 13 weeks, 26 weeks

  7. Functional Capacity

    Functional capacity, or aerobic capacity, measured by the 6-Minute Walk Test

    Time frame: Baseline, 13 weeks, 26 weeks

  8. NIH Toolbox Cognitive Battery

    Cognitive function measured by NIH Toolbox Cognitive Battery

    Time frame: Baseline, 13 weeks, 26 weeks

  9. ADAS-Cog Plus

    Cognitive function measured by ADAS-Cog Plus

    Time frame: Baseline, 13 weeks, 26 weeks

  10. Executive Functions

    The domain of executive functions measured by Trails A and B, Digits Forward and Backward, and Clock Drawing

    Time frame: Baseline, 13 weeks, 26 weeks

  11. Verbal Fluency

    Verbal fluency measured by categorical fluency

    Time frame: Baseline, 13 weeks, 26 weeks

  12. Memory

    Memory measured by the Rey Auditory Verbal Fluency

    Time frame: Baseline, 13 weeks, 26 weeks

  13. Blood Pressure

    Systolic and diastolic blood pressure

    Time frame: Baseline, 13 weeks, 26 weeks

  14. Chronotype

    Chronotype measured by questionnaire

    Time frame: Baseline, 13 weeks, 26 weeks

  15. Blood Biomarkers (OPTIONAL)

    We will draw blood to assess markers cardiometabolic health and brain health

    Time frame: Baseline, 13 weeks, 26 weeks

  16. Quality of life

    Quality of life measured by the EuroQol-5 Domain-5 Level (EQ-5D-5L)

    Time frame: Baseline, 13 weeks, 26 weeks

  17. Current Physical Activity (Self-Report)

    Physical activity outside of research study will be assessed by questionnaire

    Time frame: Baseline, 13 weeks, 26 weeks

  18. Balance and Mobility

    Balance and mobility measured by the Short Physical Performance Battery

    Time frame: Baseline, 13 weeks, 26 weeks

  19. Activities of Daily Living

    Lawton and Brody Instrumental Activities of Daily Living Scale will asssess activites of daily living

    Time frame: Baseline, 26 weeks

  20. Arterial Stiffness

    Arterial stiffness will be measured as pulse wave velocity

    Time frame: Baseline, 13 weeks, 26 weeks

  21. Sedentary Behaviour

    Time in sedentary behaviour will be measured by actigraphy over days of wear.

    Time frame: Baseline, 13 weeks, 26 weeks

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2025 (actual). Primary completion is estimated for May 2028, 36 months after the start.

Of 3,121 non-industry interventional studies with no phase under Stroke, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 46. This study's planned 36 months is above that.

Counting every sponsor, half of 3,265 studies reached it within 23 months; a quarter within 10 and three quarters within 46.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 17, 2025
First posted
Feb 26, 2025
StartActual
May 15, 2025
Primary completionEst.
May 15, 2028
CompletionEst.
Jun 30, 2028
Last update
Jun 11, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 11, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06847074
Collaborators
Vancouver Coastal Health Research Institute
Responsible party
Teresa Liu-Ambrose (Professor, University of British Columbia) — Principal investigator
First posted
Feb 26, 2025
Start date
May 15, 2025
Primary completion
May 15, 2028 (estimated)
Completion
Jun 30, 2028 (estimated)
Last update
Jun 11, 2026

Study contacts

Teresa Liu-Ambrose, PhD
Contact
teresa.ambrose@ubc.ca
604-617-8047
Ryan Stein, MSc
Contact
exsleep.strokestudy@ubc.ca
Teresa Liu-Ambrose, PhD
principal investigator · University of British Columbia

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion